Rodriguez-Otero, Paula http://orcid.org/0000-0001-5236-7785
van de Donk, Niels W. C. J.
Pillarisetti, Kodandaram
Cornax, Ingrid
Vishwamitra, Deeksha
Gray, Kathleen
Hilder, Brandi
Tolbert, Jaszianne
Renaud, Thomas
Masterson, Tara
Heuck, Christoph
Kane, Colleen
Verona, Raluca
Moreau, Philippe http://orcid.org/0000-0003-1780-8746
Bahlis, Nizar http://orcid.org/0000-0001-7353-7034
Chari, Ajai
Funding for this research was provided by:
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Article History
Received: 2 August 2023
Revised: 29 November 2023
Accepted: 5 December 2023
First Online: 2 February 2024
Change Date: 6 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-024-01018-6
Competing interests
: PRO reports a consulting or advisory role with AbbVie, BMS, GlaxoSmithKline, Janssen, Pfizer, and Sanofi; is on the speakers’ bureau for BMS, GlaxoSmithKline, Janssen, and Sanofi; has received travel, accommodations, and expenses from Pfizer; and has received honoraria from AbbVie, Celgene, GlaxoSmithKline, H3 Biomedicine, Janssen, Pfizer, and Sanofi. NWCJvdD has received research funding from Amgen, BMS, Celgene, Cellectis, Janssen, and Novartis; and reports a consulting or advisory role with AbbVie, Adaptive Biotechnologies, Amgen, Bayer, BMS, Celgene, Janssen, Novartis, Pfizer, Roche, Servier, and Takeda. KP is an employee of Janssen Oncology and report stock and other ownership interests in Johnson & Johnson/Janssen. IC is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. DV is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. KG is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. BH is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. JT is an employee of Johnson & Johnson and reports stock and other ownership in Johnson & Johnson; and has received research funding from Janssen Research & Development. TR is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. TM is an employee of Janssen Research & Development and reports stock and other ownership interests in Johnson & Johnson. CH is an employee of Janssen Research & Development; reports stock and other ownership interests in Janssen Research & Development; and reports patents, royalties, and other intellectual property in Janssen Research & Development. CK is an employee of Janssen Research & Development; reports stock and other ownership interests in Janssen Research & Development; and has received travel, accommodation, and expenses from Janssen Research & Development. PM has served in a consulting/advisory role and has received honoraria from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, and Sanofi. NB has served in a consulting/advisory role for AbbVie, Amgen, Bristol Myers Squibb, Forus, Genentech, GlaxoSmithKline, Janssen, Pfizer, Sanofi, and Takeda; has received honoraria from AbbVie, Amgen, Bristol Myers Squibb, Forus, Janssen, Pfizer, and Sanofi; has received research funding from Pfizer; and has served as a member of an IRC and/or steering committee for AbbVie, GlaxoSmithKline, and Janssen. AC reports a consulting or advisory role for AbbVie, Antengene, BMS, Genentech, Genzyme, GlaxoSmithKline, Janssen Oncology, Karyopharm Therapeutics, OncoPeptides, Seagen, Secura Bio, Shattuck Bio, Shattuck Labs, and Takeda; and has received research funding from Amgen, Celgene, Janssen, Pharmacyclics, Seagen, and Takeda.